ENDRA Life Sciences Inc. Warrants
NDRAW
NDRAW was delisted on the 12th of May, 2022.
1 hedge funds and large institutions have $2K invested in ENDRA Life Sciences Inc. Warrants in 2019 Q3 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 1 reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 1 → 1 (0)
71% less capital invested
Capital invested by funds: $7K → $2K (-$5K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$2.15K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $2K | -$2.15K | -3,232 | -31% |
|
NDRAW Hedge Fund Activity: Q3 2019 in Review
1 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in ENDRA Life Sciences Inc. Warrants (NDRAW) for Q3 2019, worth a combined $2K — down 71% from $7K a quarter earlier.
Fund positioning in NDRAW was balanced in Q3 2019: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 1 trimmed.
The largest seller was UBS Group, cutting an estimated $2.15K.
- 1 institutional investor held ENDRA Life Sciences Inc. Warrants (NDRAW) as of Q3 2019, unchanged from Q2 2019.
- Funds reported $2K of ENDRA Life Sciences Inc. Warrants stock for Q3 2019, down 71% quarter-over-quarter.
- 0 funds opened new ENDRA Life Sciences Inc. Warrants positions in Q3 2019 and 0 closed out.
- The largest ENDRA Life Sciences Inc. Warrants seller in Q3 2019 was UBS Group, an estimated $2.15K sold.
Based on aggregated 13F filings for Q3 2019.